Nightstar Announces Pricing of Initial Public Offering
September 27 2017 - 7:45PM
Business Wire
Nightstar Therapeutics plc (“Nightstar” or the “Company”), a
clinical-stage gene therapy company developing treatments for rare
inherited retinal diseases, today announced the pricing of its
initial public offering in the United States of 5,360,000 American
Depositary Shares (“ADSs”) representing 5,360,000 ordinary shares
at an initial public offering price of $14.00 per ADS for total
gross proceeds of approximately $75.0 million. All ADSs sold in the
offering were offered by Nightstar. The shares are expected to
begin trading on The NASDAQ Global Select Market on September 28,
2017 under the ticker symbol “NITE.” In addition, Nightstar has
granted the underwriters a 30-day option to purchase up to an
additional 804,000 ADSs at the initial public offering price, less
underwriting discounts and commissions. The offering is expected to
close on October 2, 2017, subject to customary closing
conditions.
Jefferies LLC, Leerink Partners LLC and BMO Capital Markets
Corp. are acting as joint book-running managers for the offering.
Wedbush Securities Inc. and Chardan are acting as co-managers.
The offering will be made only by means of a prospectus. When
available, copies of the final prospectus related to the offering
can be obtained from Jefferies LLC, Attention: Equity Syndicate
Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY
10022, or by telephone at (877) 547-6340, or by email at
Prospectus_Department@Jefferies.com; Leerink Partners LLC,
Attention: Syndicate Department, One Federal Street, 37th Floor,
Boston, MA 02110, or by telephone at (800) 808-7525 ext. 6132, or
by email at Syndicate@Leerink.com; or BMO Capital Markets Corp.,
Attention: Equity Syndicate Department, 3 Times Square, New York,
NY 10036, or by telephone at (800) 414-3627, or by email at
bmoprospectus@bmo.com.
A registration statement relating to these securities has been
filed with, and declared effective by, the U.S. Securities and
Exchange Commission (the “SEC”). Copies of the registration
statement can be accessed through the SEC’s website at www.sec.gov.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy securities, and shall not
constitute an offer, solicitation or sale in any jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of that
jurisdiction.
About Nightstar
Nightstar is a leading clinical-stage gene therapy company
focused on developing and commercializing novel one-time treatments
for patients suffering from rare inherited retinal diseases
including choroideremia, X-linked retinitis pigmentosa and Best
vitelliform macular dystrophy.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170927006448/en/
THRUST IRAlicia Davis, 910-620-3302alicia@thrustir.com
Nightstar Therapeutics Plc ADS (NASDAQ:NITE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Nightstar Therapeutics Plc ADS (NASDAQ:NITE)
Historical Stock Chart
From Apr 2023 to Apr 2024